Abivax SA Sponsored ADR $ABVX Shares Sold by Stempoint Capital LP

Stempoint Capital LP reduced its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 19.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 313,791 shares of the company’s stock after selling 77,992 shares during the quarter. Abivax makes up approximately 6.7% of Stempoint Capital LP’s holdings, making the stock its 2nd biggest position. Stempoint Capital LP’s holdings in Abivax were worth $34,941,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. UBS Group AG lifted its position in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Morgan Stanley grew its position in Abivax by 114.3% in the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new position in Abivax in the third quarter valued at $132,800,000. TCG Crossover Management LLC increased its stake in Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after buying an additional 1,055,000 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in Abivax in the 4th quarter valued at $136,199,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ABVX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and increased their price target for the company from $108.00 to $158.00 in a research report on Tuesday, June 30th. Finally, Truist Financial raised their price target on Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.50.

Abivax Trading Down 4.3%

NASDAQ ABVX opened at $118.84 on Thursday. The firm has a market capitalization of $10.37 billion, a P/E ratio of -22.81 and a beta of 0.87. The firm’s fifty day moving average price is $118.47 and its two-hundred day moving average price is $118.29. Abivax SA Sponsored ADR has a 1 year low of $67.09 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts anticipate that Abivax SA Sponsored ADR will post -3.22 EPS for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.